高质量创新成为国产药品开发主旋律，港股创新药ETF(159567)跟踪指数走势占优，中国生物制药、君实生物、来凯医药-B领涨。

有连云06-26

2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。支付体系更成熟的欧美市场给予具备差异化竞争力的国产创新药充分的交易溢价。在2023-2024年达成的4笔创新药对外授权交易中，获得超过1.5亿美元首付款的7笔均...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446438694?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-26 10:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2446438694","market":"hk","top_or_hot":-1,"title":"高质量创新成为国产药品开发主旋律，港股创新药ETF(159567)跟踪指数走势占优，中国生物制药、君实生物、来凯医药-B领涨。","media":"有连云","content":"<div>\n<p>2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。支付体系更成熟的欧美市场给予具备差异化竞争力的国产创新药充分的交易溢价。在2023-2024年达成的4笔创新药对外授权交易中，获得超过1.5亿美元首付款的7笔均...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高质量创新成为国产药品开发主旋律，港股创新药ETF(159567)跟踪指数走势占优，中国生物制药、君实生物、来凯医药-B领涨。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高质量创新成为国产药品开发主旋律，港股创新药ETF(159567)跟踪指数走势占优，中国生物制药、君实生物、来凯医药-B领涨。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 10:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b><strong>有连云</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。支付体系更成熟的欧美市场给予具备差异化竞争力的国产创新药充分的交易溢价。在2023-2024年达成的4笔创新药对外授权交易中，获得超过1.5亿美元首付款的7笔均...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","article_id":"2446438694","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2446438694","pubTimestamp":1719369706,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。进入2024年，创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","02105":"来凯医药-B","BK1583":"高瓴概念","01877":"君实生物","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","01177":"中国生物制药","BK1161":"生物科技"},"translate_title":"High-quality innovation has become the main theme of domestic drug development. The Hong Kong stock innovative drug ETF (159567) tracks the trend of the index, and China Biopharmaceuticals, Junshi Biotech, and Laikai Medicine-B lead the gains.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01177":1,"01877":1,"02105":1},"content_text":"2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。支付体系更成熟的欧美市场给予具备差异化竞争力的国产创新药充分的交易溢价。在2023-2024年达成的4笔创新药对外授权交易中，获得超过1.5亿美元首付款的7笔均为潜在的FIC或BIC药物。进入2024年，创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。充沛的医保基金结余也为进一步提升创新药医保支付占比提供了保障。相关产品： 港股创新药ETF（159567）本条资讯内容与数据仅供参考，不构成投资建议。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446438694"}